---
schema_version: "secwatch.filing_event.v1"
accession: "0001714899-24-000075"
form_type: "8-K"
ticker: "DNLI"
cik: "0001714899"
company_name: "Denali Therapeutics Inc."
filed_at: "2024-02-27T23:59:59+00:00"
generated_at: "2026-06-05T12:16:06.881981+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Denali raises $500M via PIPE at $17.07/share, adds pre-funded warrants

## Summary
- Gross proceeds of ~$500M from 3.2M shares at $17.07 and 26M pre-funded warrants at $17.06.
- Proceeds to fund R&D, accelerate BBB-crossing Transport Vehicle technology, and working capital.
- Lead investor is a U.S. healthcare-focused fund; close expected Feb 29, 2024.
- Post-close estimated cash, equivalents, and investments ~$1.5B.
- Investor with >10% ownership can appoint one board nominee under nominating agreement.

## SEC filing metadata
- accession: 0001714899-24-000075
- form_type: 8-K
- ticker: DNLI
- cik: 0001714899
- company_name: Denali Therapeutics Inc.
- filed_at: 2024-02-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1714899/000171489924000075/0001714899-24-000075-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1714899/000171489924000075/dnli-20240227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001714899-24-000075
- JSON: https://secwatch.observer/filing/0001714899-24-000075.json
- Plain text: https://secwatch.observer/filing/0001714899-24-000075.txt

## Key facts
- Material Agreements
  Denali Therapeutics Inc. entered into Purchase Agreement with the purchasers named therein valued at approximately $500 million (effective 2024-02-27).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: the purchasers named therein
  - Value: approximately $500 million
  - Effective: 2024-02-27
  source text: On February 27, 2024, Denali Therapeutics Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), for the private placement (the “Private Placement”) of (i) 3,244,689 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (the “Common Stock”), at $17.07 per Share, and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase 26,046,065 shares of Common Stock (the “Warrant Shares” and together with the Shares and the Pre-Funded Warrants, the “Securities”), at a purchase price of $17.06 per Pre-Funded Warrant.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1714899/000171489924000075/0001714899-24-000075-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.